Wells Fargo raises Amgen stock price target to $435 on drug trial outlook
Wells Fargo raises Amgen stock price target to $435 on drug trial outlook Investing.com
Covered in this story
Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.